Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Account Payables
Amounts the company owes suppliers for goods and services received.
Benitec Biopharma Inc.NASDAQ: BNTC
Account Payables · Q3 FY2026 · quarter ended Mar 2026
Account payables rises 46.7% from a year ago
Account payables stood at $635K at the end of Q3 FY2026, up 46.7% from a year earlier and down 37.5% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.
Context
- Account payables amounted to 0.3% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +46.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 201K USD
- Year-over-year change
- -85.1%
- 4-year CAGR
- -7.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 201K | -85.1% |
| FY2024 | 2024-06-30 | 1.35M | +18.5% |
| FY2023 | 2023-06-30 | 1.14M | +170.1% |
| FY2022 | 2022-06-30 | 422K | +54.0% |
| FY2021 | 2021-06-30 | 274K | — |
Account Payables vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 account payables of $635K is the lowest of the 10 companies compared; the peer median is $3.24M.
- Its year-over-year change of +46.7% is the 4th highest of 10, against a peer median of -5.5%.
- Account payables amounts to 0.3% of total assets for BNTC, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.57M | +179.0% | -0.7% | 5.1% | |
| Mar 2026 | $5.56M | -13.6% | -0.1% | 1.3% | |
| Mar 2026 | $4.69M | +53.0% | +46.2% | 1.8% | |
| Mar 2026 | $3.53M | +52.4% | +61.5% | 1.3% | |
| Mar 2026 | $3.24M | +0.5% | -8.4% | 5.7% | |
| Mar 2026 | $3.12M | -52.2% | -5.9% | 19.8% | |
| Dec 2025 | $3.07M | -44.4% | -51.3% | 0.6% | |
| Mar 2026 | $1.87M | -58.0% | +79.7% | 0.4% | |
| Mar 2026 | $1.79M | -5.5% | -25.4% | 0.8% | |
| Mar 2026 | $635K | +46.7% | -21.9% | 0.3% | |
| Peer median (excluding BNTC) | $3.24M | -5.5% | -0.7% | 1.3% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.